CTOs on the Move

Ampio Pharmaceuticals

www.ampiopharma.com

 
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ampio Pharmaceuticals raised $12M on 06/18/2019

Similar Companies

X-elitec

X-elitec is a Fuquay Varina, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Charm Medical Supply

Charm Medical Supply is a Pembroke, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wimbledon Health Partners

Wimbledon Health Partners formed in 2013 to meet the need for on-site diagnostic testing at physicians’ offices. The industry leader, Wimbledon Health Partners provides physicians with state-of-the-art, in-office testing to detect circulatory conditions using vascular ultrasound and electro- and echocardiography. Nerve conduction velocity testing is also used to support diagnosis of problems related to the nervous and muscular systems. Wimbledon Athletics, the newest division of Wimbledon Health Partners, is pioneering the way for high schools, colleges and universities to test students for unsuspected heart abnormalities to help minimize sudden cardiac death among young athletes.

Framingham Heart Study

Since our beginning in 1948, the Framingham Heart Study, under the direction of the National Heart, Lung and Blood Institute (NHLBI), formerly known as the National Heart Institute, has been committed to identifying the common factors or characteristics that contribute to cardiovascular disease (CVD). We have followed CVD development over a long period of time in three generations of participants.

Satellite Healthcare

Making Life Better for Those Living with Kidney Disease. For nearly 40 years, our mission has remained unchanged. From the patient chair side to the boardroom, this powerful yet practical principle guides our daily clinical work as well as our leadership decisions.